260 research outputs found
Changes in the Structuredness of Cytoplasmic Matrix of Lymphocytes as a Diagnostic and Prognostic Test for Cancer
No full textSummary.-The method of measuring changes in the structuredness of cytoplasmic matrix (SCM) in single cells is described. Data on SCM distributions and fractions of human lymphocyte populations which respond to stimulations with PHA and CaBP in healthy donors and patients with malignant disorders are presented. LYMPHOCYTES from patients with malignant diseases can be differentiated from those of healthy donors or donors with non-malignant disorders on the basis of changes in the structuredness of cyto-plasmic matrix (SCM) induced by cancer basic protein (CaBP), tumour-tissue asso-ciated antigens and phytohaemagglutinin (PHA) (Cercek, Cercek and Garrett, 1 974b; Cercek, Cercek and Franklin, 1974a; Cercek and Cercek, 1975a, b). Changes in the SCM are measured on cell suspensions with the technique of fluorescence polarization in a fluorescence spectrophotometer of high sensitivity (Cercek, Cercek and Ockey, 1973). These measurements yield data on average changes in the SCM over whole cell populations, and cannot yield estimates of the percentages of cells which change their SCM on stimulation. We have, therefore, extended the technique of fluorescence polarization to measurements of changes in the SCM on single cells. This paper describes the SCM technique for single cells and presents data on SCM distributions and fractions of lym-phocyte populations which respond to stimulations with CaBP and PHA in healthy donors and in patients with malignant disorders
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL
No full textBackground and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative.Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a number of other diseases. The recommendations, in line with the European guidelines, are presented.Results: A thorough evaluation of clinical data by the expert working group resulted in recommendations to consider non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB), remnant cholesterol and lipoprotein(a) (Lp[ a]) as biomarkers of residual CV risk in patients with CVD. Elevated Lp(a) levels were also suggested to be a causal factor. The experts highlighted the significance of nonHDL-C and triglycerides (TG) in atherogenic dyslipidaemia associated with type 2 diabetes, metabolic syndrome, chronic kidney disease (CKD) and familial combined hyperlipidaemia (FCH). The working group recommended combinatorial therapeutic approaches in high-risk patients, including agents impacting on TG and HDL-C levels.Conclusions: Evaluation of a lipoprotein landscape when LDL-C levels remain low strongly supports the role of non-HDL-C, Lp(a) and TGs in identifying patients with increased residual risk of CV and in selecting their treatment strategy. (C) 2017 Elsevier B.V. All rights reserved
Response to "Comments on the Fluorescein Excitation and Emission Polarization Spectra in Living Cells"
No full text
Changes in the structuredness of cytoplasmic matrix (SCM) in human lymphocytes induced by PHA and cancer basic protein as measured in single cells
No full textComments on “the SCM test for cancer. An evaluation in terms of lymphocytes from healthy donors and cancer patients”
No full textChanges in scm-responses of lymphocytes in mice after implantation with ehrlich ascites cells.
No full text
Effects of osmolality and density of gradients on the isolation of SCM-responding lymphocytes
No full textInvolvement of mitochondria in changes in fluorescein excitation and emission polarization spectra in living cells
No full textThe comparison of fluorescein polarization spectra in living cells and in isolated subcellular structures identified the mitochondria as the cytoplasmic domain in which on excitation at 470 nm the sharp fluorescein emission polarization peak at 510 nm is formed. Changes in the emission polarization peak during the cell cycle or those induced by growth stimulators and inhibitors reflect structural changes in the mitochondria on their transition from the resting, orthodox into the active, ATP-generating, condensed conformation and vice versa. Possible mechanisms for the formation of the sharp emission polarization peak are discussed
- …
